Home › Funds › LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA › REGN

LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA position in REGN

REGENERON PHARMACEUTICALS · Health Care

LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA reported holding 65,875 shares of REGN (REGENERON PHARMACEUTICALS) in its Q2 2026 13F filing — a position valued at US$41.1M, representing 0.40% of its reported portfolio and ranking #49 among its reported holdings. LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA has disclosed REGN holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)65.88K sh
Reported value held$41.08M
Portfolio Weight0.40%
First reportedQ3 2023
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA's REGN position evolved

LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA first disclosed a stake in REGN in Q3 2023 at 43,917 shares (US$36.0M). The position peaked in Q2 2024 at 103,680 shares, worth US$113.5M. Across 12 filings, LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA increased the stake 5 time(s), trimmed it 6 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 65,875 shares valued at US$41.1M — a reduction of -6,555 shares quarter over quarter.. Notable position changes include a 40% increase in Q4 2023 (shares rose 10% over the following quarter), a 42% increase in Q1 2024 (shares rose 9% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 43.92K $35.96M New
Q4 2023 61.45K $57.93M Add
Q1 2024 87.27K $78.56M Add
Q2 2024 103.68K $113.53M Add
Q3 2024 109.48K $101.70M Add
Q4 2024 106.09K $72.64M Reduce
Q1 2025 96.47K $56.71M Reduce
Q2 2025 99.91K $52.45M Add
Q3 2025 91.73K $52.81M Reduce
Q4 2025 86.97K $67.08M Reduce
Q1 2026 72.43K $54.24M Reduce
Q2 2026 65.88K $41.08M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About REGN and 13F data

REGN (REGENERON PHARMACEUTICALS) is a Health Care company. 31 other funds we track also report a position in REGN — the largest reported positions include Dodge & Cox (US$3.04B), DODGE & COX (US$3.04B), LOOMIS SAYLES & CO L P (US$1.16B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding REGN

All REGN fund holders →

FAQ

How long has LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA held REGN?

LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA has disclosed REGN holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA's current position in REGN?

As of Q2 2026, LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA holds 65.88K shares of REGN (REGENERON PHARMACEUTICALS), valued at $41.08M, representing 0.40% of its reported portfolio and ranking #49.

Has LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA been buying or selling REGN?

In the latest 13F filing (Q2 2026), LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA reduced its position in REGN. The position peaked in Q2 2024 at 103.68K shares.

Which other funds hold REGN?

Other major institutional holders of REGN include Dodge & Cox, DODGE & COX, LOOMIS SAYLES & CO L P, among 31 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.